New targets for rapid antidepressant action
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Current therapeutic options for major depressive disorder (MDD) and bipolar disorder (BD) are associated with a lag of onset that can prolong distress and impairment for patients, and their antidepressant efficacy is often limited. All currently approved antidepressant medications for MDD act primarily through monoaminergic mechanisms. Glutamate is the major excitatory neurotransmitter in the central nervous system, and glutamate and its cognate receptors are implicated in the pathophysiology of MDD, and in the development of novel therapeutics for this disorder. The rapid and robust antidepressant effects of the N-methyl-D-aspartate (NMDA) antagonist ketamine were first observed in 2000. Since then, other NMDA receptor antagonists have been studied in MDD. Most have demonstrated relatively modest antidepressant effects compared to ketamine, but some have shown more favorable characteristics. This article reviews the clinical evidence supporting the use of novel glutamate receptor modulators with direct affinity for cognate receptors: 1) non-competitive NMDA receptor antagonists (ketamine, memantine, dextromethorphan, AZD6765); 2) subunit (GluN2B)-specific NMDA receptor antagonists (CP-101,606/traxoprodil, MK-0657); 3) NMDA receptor glycine-site partial agonists (GLYX-13); and 4) metabotropic glutamate receptor (mGluR) modulators (AZD2066, RO4917523/basimglurant). We also briefly discuss several other theoretical glutamate receptor targets with preclinical antidepressant-like efficacy that have yet to be studied clinically; these include α-amino-3-hydroxyl-5-methyl-4-isoxazoleproprionic acid (AMPA) agonists and mGluR2/3 negative allosteric modulators. The review also discusses other promising, non-glutamatergic targets for potential rapid antidepressant effects, including the cholinergic system (scopolamine), the opioid system (ALKS-5461), corticotropin releasing factor (CRF) receptor antagonists (CP-316,311), and others.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Malenka, R. C., & Bear, M. F. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.012 · Cited by 3,968
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Toward the future of psychiatric diagnosis: the seven pillars of RDoC
Cuthbert, B. N., & Insel, T. R. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-126 · Cited by 3,053
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Research works printed but not linked: 146
- Abdallah, 2015, Ketamine as a promising prototype for a new generation of rapid-acting antidepressants, Ann. N.Y. Acad. Sci., 1344, 66, 10.1111/nyas.12718 · DOI · Paper page
- Ahn, 2008, Chronotype distribution in bipolar I disorder and schizophrenia in a Korean sample, Bipolar Disord., 10, 271, 10.1111/j.1399-5618.2007.00573.x · DOI
- Alaerts, 2006, Lack of association of an insertion/deletion polymorphism in the G protein-coupled receptor 50 with bipolar disorder in a Northern Swedish population, Psychiatr. Genet., 16, 235, 10.1097/01.ypg.0000242193.28526.b3 · DOI
- Armstrong, 1993, Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS), Pharmacol. Biochem. Behav., 46, 45, 10.1016/0091-3057(93)90315-K · DOI
- Ball, 2014, Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder, Hum. Psychopharmacol., 29, 568, 10.1002/hup.2444 · DOI
- Bersani, 2000, Melatonin add-on in manic patients with treatment resistant insomnia, Biol. Psychiatry, 24, 185
- Bertaina-Anglade, 2006, Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model, Behav. Pharmacol., 17, 703, 10.1097/FBP.0b013e3280116e5c · DOI
- Beurel, 2011, Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice, Mol. Psychiatry, 16, 1068, 10.1038/mp.2011.47 · DOI · Paper page
- Bleakman, 2007, AMPA receptors in the therapeutic management of depression, CNS Neurol. Disord. Drug Targets, 6, 117, 10.2174/187152707780363258 · DOI
- Bourin, 2009, Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression, Curr. Pharm. Des., 15, 1675, 10.2174/138161209788168056 · DOI
- Boyer, 1998, Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study, J. Mol. Neurosci., 10, 219, 10.1007/BF02761776 · DOI
- Bredt, 2015, Translating depression biomarkers for improved targeted therapies, Neurosci. Biobehav. Rev., 59, 1, 10.1016/j.neubiorev.2015.09.013 · DOI
- Calabrese, 2007, Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data, Bipolar Disord., 9, 628, 10.1111/j.1399-5618.2007.00507.x · DOI · Paper page
- Cao, 2010, Mammalian target of rapamycin signaling modulates photic entrainment of the suprachiasmatic circadian clock, J. Neurosci., 30, 6302, 10.1523/JNEUROSCI.5482-09.2010 · DOI
- Cardinali, 2011, Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications, Neuroendocrinology, 93, 133, 10.1159/000324699 · DOI
- Carlson, 2013, Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study, Biol. Psychiatry, 73, 1213, 10.1016/j.biopsych.2013.02.008 · DOI · Paper page
- Castren, 2010, The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity, Dev. Neurobiol., 70, 289, 10.1002/dneu.20758 · DOI · Paper page
- Chaki, 2013, mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants, Neuropharmacology, 66, 40, 10.1016/j.neuropharm.2012.05.022 · DOI
- Chilukuri, 2014, Acute antidepressant effects of intramuscular versus intravenous ketamine, Indian J. Psychol. Med., 36, 71, 10.4103/0253-7176.127258 · DOI · Paper page
- Chung, 1992, mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists, Cell, 69, 1227, 10.1016/0092-8674(92)90643-Q · DOI · Paper page
- Covington, 2010, From synapse to nucleus: novel targets for treating depression, Neuropharmacology, 58, 683, 10.1016/j.neuropharm.2009.12.004 · DOI · Paper page
- Dale, 2015, Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs, Biochem. Pharmacol., 95, 81, 10.1016/j.bcp.2015.03.011 · DOI · Paper page
- Dawson, 2014, Subanesthetic ketamine treatment promotes abnormal interactions between neural subsystems and alters the properties of functional brain networks, Neuropsychopharmacology, 39, 1786, 10.1038/npp.2014.26 · DOI
- Day, 2012, Epigenetic treatments for cognitive impairments, Neuropsychopharmacology, 37, 247, 10.1038/npp.2011.85 · DOI
- DeLorenzo, 2015, Invivo ketamine-induced changes in [C]ABP688 binding to metabotropic glutamate receptor subtype 5, Biol. Psychiatry, 77, 266, 10.1016/j.biopsych.2014.06.024 · DOI
- Denk, 2011, Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation, Am. J. Psychiatry, 68, 751, 10.1176/appi.ajp.2011.11010128 · DOI
- Drevets, 2013, Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review, Biol. Psychiatry, 73, 1156, 10.1016/j.biopsych.2012.09.031 · DOI · Paper page
- Duman, 2015, Spine synapse remodeling in the pathophysiology and treatment of depression, Neurosci. Lett., 601, 20, 10.1016/j.neulet.2015.01.022 · DOI · Paper page
- Duman, 2009, Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression, Dialogues Clin. Neurosci., 11, 239, 10.31887/DCNS.2009.11.3/rsduman · DOI · Paper page
- Dutta, 2015, Ketamine and other potential glutamate antidepressants, Psychiatry Res., 225, 1, 10.1016/j.psychres.2014.10.028 · DOI
- Dwyer, 2013, Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants, Biol. Psychiatry, 73, 1189, 10.1016/j.biopsych.2012.11.011 · DOI
- Emnett, 2013, Indistinguishable synaptic pharmacodynamics of the N-methyl-d-aspartate receptor channel blockers memantine and ketamine, Mol. Pharmacol., 84, 935, 10.1124/mol.113.089334 · DOI
- Espino, 2011, Role of melatonin on diabetes-related metabolic disorders, World J. Diabetes, 2, 82, 10.4239/wjd.v2.i6.82 · DOI
- Garcia, 2008, Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus, Prog. Neuropsychopharmacol. Biol. Psychiatry, 32, 140, 10.1016/j.pnpbp.2007.07.027 · DOI · Paper page
- Geoffrey, 2015, Melatonin and melatonin agonists as adjunctive treatments in bipolar disorders, Curr. Pharm. Des., 21, 3352, 10.2174/1381612821666150619093448 · DOI
- Gruber, 2009, Sleep functioning in relation to mood, function, and quality of life at entry to the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), J. Affect Disord., 114, 41, 10.1016/j.jad.2008.06.028 · DOI
- Hallam, 2006, The heritability of melatonin secretion and sensitivity to bright nocturnal light in twins, Psychoneuroendocrinology, 31, 867, 10.1016/j.psyneuen.2006.04.004 · DOI · Paper page
- Hallam, 2005, Low doses of lithium carbonate reduce melatonin light sensitivity in healthy volunteers, Int. J. Neuropsychopharmacol., 8, 255, 10.1017/S1461145704004894 · DOI
- Hallam, 2005, Effect of sodium valproate on nocturnal melatonin sensitivity to light in healthy volunteers, Neuropsychopharmacology, 30, 1400, 10.1038/sj.npp.1300739 · DOI
- Hallam, 2005, Melatonin sensitivity to light in monozygotic twins discordant for bipolar I disorder, Aust. N.Z. J. Psychiatry, 39, 947, 10.1080/j.1440-1614.2005.01705_1.x · doi:10.1080/j.1440-1614.2005.01705_1.x
- Hashimoto, 2007, Increased levels of glutamate in brains from patients with mood disorders, Biol. Psychiatry, 62, 1310, 10.1016/j.biopsych.2007.03.017 · DOI · Paper page
- Heitman, 1991, Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast, Science, 253, 905, 10.1126/science.1715094 · DOI · Paper page
- Hirota, 1996, Ketamine: its mechanism(s) of action and unusual clinical uses, Br. J. Anaesth., 77, 441, 10.1093/bja/77.4.441 · DOI · Paper page
- Hirota, 1999, Stereoselective interaction of ketamine with recombinant μ, κ and δ opiod receptors expressed in chinese hamster ovary cells, Anesthesiology, 90, 174, 10.1097/00000542-199901000-00023 · DOI · Paper page
- Hoeffer, 2010, mTOR signaling: at the crossroads of plasticity, memory and disease, Trends Neurosci., 33, 67, 10.1016/j.tins.2009.11.003 · DOI · Paper page
- Jaffe, 2013, Scopolamine as an antidepressant: a systematic review, Clin. Neuropharmacol., 36, 24, 10.1097/WNF.0b013e318278b703 · DOI
- Karasawa, 2005, AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist, Brain Res., 1042, 92, 10.1016/j.brainres.2005.02.032 · DOI
- Kennedy, 2006, Placebo-controlled trial of agomelatine in the treatment of major depressive disorder, Eur. Neuropsychopharmacol., 16, 93, 10.1016/j.euroneuro.2005.09.002 · DOI · Paper page
- Kennedy, 1996, Nocturnal melatonin and 24-hour 6-sulphatoxymelatonin levels in various phases of bipolar affective disorder, Psychiatry Res., 63, 219, 10.1016/0165-1781(96)02910-1 · DOI
- Khajavi, 2012, Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study, J. Clin. Psychiatry, 73, 1428, 10.4088/JCP.12m07706 · DOI
- Klimek, 1994, The effect of MK-801 and imipramine on beta-adrenergic and 5-HT2 receptors in the chronic mild stress model of depression in rats, Pol. J. Pharmacol., 46, 67
- Knoll, 2010, Dynorphin, stress, and depression, Brain Res., 1314, 56, 10.1016/j.brainres.2009.09.074 · DOI · Paper page
- Kocsis, 2013, Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits, CNS Neurosci. Ther., 19, 437, 10.1111/cns.12081 · DOI
- Koshikawa, 1989, Rapid development of brain beta-adrenoceptor down-regulation induced by phenelzine: subcellular studies, Eur. J. Pharmacol., 170, 101, 10.1016/0014-2999(89)90141-6 · doi:10.1016/0014-2999(89)90141-6
- Kotermanski, 2009, Memantine binding to a superficial site on NMDA receptors contributes to partial trapping, J. Physiol., 587, 4589, 10.1113/jphysiol.2009.176297 · DOI
- Kramer, 1998, Distinct mechanism for antidepressant activity by blockade of central substance P receptors, Science, 281, 1640, 10.1126/science.281.5383.1640 · DOI · Paper page
- Kramer, 2004, Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression, Neuropsychopharmacology, 29, 385, 10.1038/sj.npp.1300260 · DOI · Paper page
- Lauterbach, 2011, Dextromethorphan as a potential rapid-acting antidepressant, Med. Hypotheses, 76, 717, 10.1016/j.mehy.2011.02.003 · DOI
- Layer, 1995, Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715), Pharmacol. Biochem. Behav., 52, 621, 10.1016/0091-3057(95)00155-P · DOI
- Legutko, 2001, Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator, Neuropharmacology, 40, 1019, 10.1016/S0028-3908(01)00006-5 · DOI
- Leibenluft, 1997, Effects of exogenous melatonin administration and withdrawal in five patients with rapid-cycling bipolar disorder, J. Clin. Psychiatry, 58, 383, 10.4088/JCP.v58n0902 · DOI
- Lewy, 1985, Supersensitivity to light: possible trait marker for manic-depressive illness, Am. J. Psychiatry, 142, 725, 10.1176/ajp.142.6.725 · DOI · Paper page
- Lewy, 1981, Manic-depressive patients may be supersensitive to light, Lancet, 1, 383, 10.1016/S0140-6736(81)91697-4 · DOI · Paper page
- Li, 2011, Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure, Biol. Psychiatry, 69, 754, 10.1016/j.biopsych.2010.12.015 · DOI · Paper page
- Linden, 2000, Expression of neurotrophins BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotropic agents, J. Mol. Neurosci., 14, 27, 10.1385/JMN:14:1-2:027 · DOI
- Liu, 2004, Muscarinic receptors modulate the mRNA expression of NMDA receptors in brainstem and the release of glutamate in periaqueductal grey during morphine withdrawal in rats, Sheng Li Xue Bao, 56, 95
- Livingstone, 2010, Mechanisms governing the control of mRNA translation, Phys. Biol., 7, 021001, 10.1088/1478-3975/7/2/021001 · DOI
- Loo, 2002, Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study, Int. Clin. Psychopharmacol., 17, 239, 10.1097/00004850-200209000-00004 · DOI · Paper page
- Lozano, 2008, Effects of subcallosal cingulate deep brain stimulation on negative self-bias in patients with treatment-resistant depression, Biol. Psychiatry, 64, 461, 10.1016/j.biopsych.2008.05.034 · DOI · Paper page
- Machado-Vieira, 2011, Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions, CNS Neurosci. Ther., 17, 699, 10.1111/j.1755-5949.2010.00203.x · DOI
- Machado-Vieira, 2009, Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders, Curr. Pharm. Des., 15, 1595, 10.2174/138161209788168010 · DOI
- Machado-Vieira, 2014, Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach, World J Biol. Psychiatry, 15, 84, 10.3109/15622975.2013.830775 · DOI
- Machado-Vieira, 2015, Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorder, Eur. Neuropsychopharmacol., 25, 468, 10.1016/j.euroneuro.2015.02.002 · DOI
- Maes, 1998, Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity, Acta Psychiatr. Scand., 97, 302, 10.1111/j.1600-0447.1998.tb10004.x · DOI · Paper page
- Maj, 1991, Antidepressant drugs increase the locomotor hyperactivity induced by MK-801 in rats, J. Neural Transm. Gen. Sect., 85, 169, 10.1007/BF01244943 · DOI
- McClung, 2007, Circadian genes, rhythms and the biology of mood disorders, Pharmacol. Ther., 114, 222, 10.1016/j.pharmthera.2007.02.003 · DOI · Paper page
- Mealing, 1999, Differences in degree of trapping of low-affinity uncompetitive N-methyl-d-aspartic acid receptor antagonists with similar kinetics of block, J. Pharmacol. Exp. Ther., 288, 204, 10.1016/S0022-3565(24)37943-1 · DOI · Paper page
- Meloni, 1993, Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats, Pharmacol. Biochem. Behav., 46, 423, 10.1016/0091-3057(93)90374-3 · DOI
- Menniti, 2013, Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks, Curr. Top. Med. Chem., 13, 26, 10.2174/1568026611313010005 · DOI
- Messias, 2012, Dextromethorphan and quinidine combination in emotional lability associated with depression: a case report, Prim Care Companion CNS Disord, 14, I01400
- Millan, 2005, Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade, Psychopharmacology (Berl.), 177, 448, 10.1007/s00213-004-1962-z · DOI · Paper page
- Mjellem, 1993, Reduction of NMDA-induced behaviour after acute and chronic administration of desipramine in mice, Neuropharmacology, 32, 591, 10.1016/0028-3908(93)90055-8 · DOI
- Montgomery, 2007, Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine, Int. Clin. Psychopharmacol., 22, 283, 10.1097/YIC.0b013e3280c56b13 · DOI
- Moryl, 1993, Potential antidepressive properties of amantadine, memantine and bifemelane, Pharmacol. Toxicol., 72, 394, 10.1111/j.1600-0773.1993.tb01351.x · DOI
- Moskal, 2014, GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists, Expert. Opin. Investig. Drugs, 23, 243, 10.1517/13543784.2014.852536 · DOI
- Musazzi, 2013, The action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptors, Biol. Psychiatry, 73, 1180, 10.1016/j.biopsych.2012.11.009 · DOI · Paper page
- Nagayama, 1996, Chronic administration of imipramine and lithium changes the phase-angle relationship between the activity and core body temperature circadian rhythms in rats, Chronobiol. Int., 13, 251, 10.3109/07420529609020905 · DOI
- Nathan, 1999, Melatonin sensitivity to dim white light in affective disorders, Neuropsychopharmacology, 21, 408, 10.1016/S0893-133X(99)00018-4 · DOI
- Nations, 2012, Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial, J. Psychopharmacol., 26, 1525, 10.1177/0269881112458728 · DOI
- Nduhirabandi, 2011, Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet-induced obesity, J. Pineal Res., 50, 171, 10.1111/j.1600-079X.2010.00826.x · DOI · Paper page
- Neubauer, 2008, A review of ramelteon in the treatment of sleep disorders, Neuropsychiatr. Dis. Treat., 4, 69, 10.2147/NDT.S483 · DOI
- Niciu, 2014, Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds, Annu. Rev. Pharmacol. Toxicol., 54, 119, 10.1146/annurev-pharmtox-011613-135950 · DOI · Paper page
- Norris, 2013, A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder, J. Affect Disord., 144, 141, 10.1016/j.jad.2012.06.023 · DOI
- Nowak, 1998, Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors, Eur. J. Pharmacol., 342, 367, 10.1016/S0014-2999(97)01589-6 · DOI
- Nowak, 1993, Adaptive changes in the N-methyl-d-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid, J. Pharmacol. Exp. Ther., 265, 1380, 10.1016/S0022-3565(25)38235-2 · DOI · Paper page
- Nurnberger, 2000, Melatonin suppression by light in euthymic bipolar and unipolar patients, Arch. Gen. Psychiatry, 57, 572, 10.1001/archpsyc.57.6.572 · DOI · Paper page
- Nurnberger, 1988, Supersensitivity to melatonin suppression by light in young people at high risk for affective disorder. A preliminary report, Neuropsychopharmacology, 1, 217, 10.1016/0893-133X(88)90020-6 · DOI
- O’Neill, 1999, A single pretreatment with MK-801 or cocaine enhances their locomotor stimulant effects in rats, Brain Res., 834, 103, 10.1016/S0006-8993(99)01580-2 · DOI
- O’Neill, 2004, AMPA receptor potentiators for the treatment of CNS disorders, Curr. Drug Targets CNS Neurol. Disord., 3, 181, 10.2174/1568007043337508 · DOI · Paper page
- O’Neill, 2007, AMPA receptor potentiators: application for depression and Parkinson's disease, Curr. Drug Targets, 8, 603, 10.2174/138945007780618517 · DOI
- Ohgi, 2015, Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders, Curr. Mol. Med., 15, 206, 10.2174/1566524015666150330143008 · DOI · Paper page
- Pacchierotti, 2001, Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry, Front. Neuroendocrinol., 22, 18, 10.1006/frne.2000.0202 · DOI · Paper page
- Papp, 2003, Effect of agomelatine in the chronic mild stress model of depression in the rat, Neuropsychopharmacology, 28, 694, 10.1038/sj.npp.1300091 · DOI · Paper page
- Paul, 1994, Adaptation of the N-methyl-d-aspartate receptor complex following chronic antidepressant treatments, J. Pharmacol. Exp. Ther., 269, 95, 10.1016/S0022-3565(25)38715-X · DOI · Paper page
- Paul, 1992, Down-regulation of cortical beta-adrenoceptors by chronic treatment with functional NMDA antagonists, Psychopharmacology (Berl.), 106, 285, 10.1007/BF02801986 · DOI
- Petty, 1985, Intracortical glutamate injection produces helpless-like behavior in the rat, Pharmacol. Biochem. Behav., 22, 531, 10.1016/0091-3057(85)90270-9 · DOI
- Pilc, 2013, Glutamate-based antidepressants: preclinical psychopharmacology, Biol. Psychiatry, 73, 1125, 10.1016/j.biopsych.2013.01.021 · DOI
- Preskorn, 2008, An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist CP-101,606, in patients with treatment-refractory major depressive disorder, J. Clin. Psychopharmacol., 28, 631, 10.1097/JCP.0b013e31818a6cea · DOI · Paper page
- Przegalinski, 1997, Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist, Neuropharmacology, 36, 31, 10.1016/S0028-3908(96)00157-8 · DOI
- Quiroz, 2014, The efficacy and safety of basimglurant as adjunctive therapy in major depression; a randomized, double-blind, placebo controlled study, Neuropsychopharmacology, 39, S376
- Rantamaki, 2008, Targeting TrkB neurotrophin receptor to treat depression, Expert Opin Ther Targets, 12, 705, 10.1517/14728222.12.6.705 · DOI · Paper page
- Rawls, 1998, Muscarinic receptors regulate extracellular glutamate levels in the rat striatum: An in vivo microdialysis study, J. Pharmacol. Exp. Ther., 286, 91, 10.1016/S0022-3565(24)37561-5 · DOI
- Redman, 1998, Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal, J. Biol. Rhythms, 13, 39, 10.1177/074873098128999907 · DOI
- Reiter, 2009, Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin, Crit. Rev. Biochem. Mol. Biol., 44, 175, 10.1080/10409230903044914 · DOI · Paper page
- Reynolds, 1988, [3H]MK801 binding to the N-methyl-d-aspartate receptor reveals drug interactions with the zinc and magnesium binding sites, J. Pharmacol. Exp. Ther., 247, 1025, 10.1016/S0022-3565(25)13253-9 · doi:10.1016/s0022-3565(25)13253-9
- Robson, 2012, Evaluation of sigma (sigma) receptors in the antidepressant-like effects of ketamine in vitro and in vivo, Eur. Neuropsychopharmacol., 22, 308, 10.1016/j.euroneuro.2011.08.002 · DOI
- Romo-Nava, 2014, Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial, Bipolar Disord., 16, 410, 10.1111/bdi.12196 · DOI
- Salvatore, 2008, Circadian activity rhythm abnormalities in ill and recovered bipolar I disorder patients, Bipolar Disord., 10, 256, 10.1111/j.1399-5618.2007.00505.x · DOI · Paper page
- Sanacora, 2012, Towards a glutamate hypothesis of depression. An emerging fronteir of neuropsychopharmacology for mood disorders, Neuropharmacology, 62, 63, 10.1016/j.neuropharm.2011.07.036 · DOI · Paper page
- Saricicek, 2011, Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial, J. Clin. Psychiatry, 72, 744, 10.4088/JCP.09m05659gre · DOI
- Scarr, 2003, Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder, Bipolar Disord., 5, 257, 10.1034/j.1399-5618.2003.00024.x · DOI
- Shah, 2014, Therapeutic modalities for treatment resistant depression: focus on vagal nerve stimulation and ketamine, Clin. Psychopharmacol. Neurosci., 12, 83, 10.9758/cpn.2014.12.2.83 · DOI
- Sills, 1989, Tricyclic antidepressants and dextromethorphan bind with higher affinity to the phencyclidine receptor in the absence of magnesium and l-glutamate, Mol. Pharmacol., 36, 160, 10.1016/S0026-895X(25)00612-1 · DOI
- Singh, 2014, What is hydroxynorketamine and what can it bring to neurotherapeutics?, Expert. Rev. Neurother., 14, 1239, 10.1586/14737175.2014.971760 · DOI
- Skolnick, 1999, Antidepressants for the new millennium, Eur. J. Pharmacol., 375, 31, 10.1016/S0014-2999(99)00330-1 · DOI · Paper page
- Skolnick, 2002, Modulation of glutamate receptors: strategies for the development of novel antidepressants, Amino Acids, 23, 153, 10.1007/s00726-001-0121-7 · DOI
- Skolnick, 1996, Adaptation of N-methyl-d-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression, Pharmacopsychiatry, 29, 23, 10.1055/s-2007-979537 · DOI · Paper page
- Srinivasan, 2006, Melatonin in mood disorders, World J Biol. Psychiatry, 7, 138, 10.1080/15622970600571822 · DOI · Paper page
- Thomson, 2005, Sex-specific association between bipolar affective disorder in women and GPR50, an X-linked orphan G protein-coupled receptor, Mol. Psychiatry, 10, 470, 10.1038/sj.mp.4001593 · DOI
- Tizabi, 2012, Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar–Kyoto rats, Neuroscience, 213, 72, 10.1016/j.neuroscience.2012.03.052 · DOI · Paper page
- Van Oekelen, 2003, 5-HT2A and 5-HT2C receptors and their atypical regulation properties, Life Sci., 72, 2429, 10.1016/S0024-3205(03)00141-3 · DOI · Paper page
- Vetulani, 1984, Complex action of antidepressant treatment on central adrenergic system: possible relevance to clinical effects, Pharmacopsychiatry, 17, 16, 10.1055/s-2007-1017401 · doi:10.1055/s-2007-1017401
- Voleti, 2013, Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses, Biol. Psychiatry, 74, 742, 10.1016/j.biopsych.2013.04.025 · DOI · Paper page
- Whalley, 1991, Melatonin response to bright light in recovered, drug-free, bipolar patients, Psychiatry Res., 38, 13, 10.1016/0165-1781(91)90048-T · DOI
- Wong, 1996, Effects of NMDA receptor antagonists on inhibition of morphine tolerance in rats: binding at μ-opioid receptors, Eur. J. Pharmacol., 297, 27, 10.1016/0014-2999(95)00728-8 · DOI
- Wood, 2009, Replicable differences in preferred circadian phase between bipolar disorder patients and control individuals, Psychiatry Res., 166, 201, 10.1016/j.psychres.2008.03.003 · DOI · Paper page
- Wu, 1990, The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis, Am. J. Psychiatry, 147, 14, 10.1176/ajp.147.1.14 · DOI · Paper page
- Wyatt, 2006, Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent, Sleep, 29, 609, 10.1093/sleep/29.5.609 · DOI · Paper page
- Yanagihara, 2003, Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers, Biopharm. Drug Dispos., 24, 37, 10.1002/bdd.336 · DOI · Paper page
- Yilmaz, 2002, Prolonged effect of an anesthetic dose of ketamine on behavioral despair, Pharmacol. Biochem. Behav., 71, 341, 10.1016/S0091-3057(01)00693-1 · DOI · Paper page
- Yu, 2013, Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway, Psychopharmacology (Berl.), 225, 361, 10.1007/s00213-012-2823-9 · DOI
- Zarate, 2013, Human biomarkers of rapid antidepressant effects, Biol. Psychiatry, 73, 1142, 10.1016/j.biopsych.2012.11.031 · DOI
- Zarate, 2005, An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression, Biol. Psychiatry, 57, 430, 10.1016/j.biopsych.2004.11.023 · DOI · Paper page
- Zimmer, 2015, Imaging in vivo glutamate fluctuations with [(11)C]ABP688: a GLT-1 challenge with ceftriaxone, J. Cereb. Blood Flow Metab., 35, 1169, 10.1038/jcbfm.2015.35 · DOI
- Zobel, 2000, Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated, J. Psychiatr. Res., 34, 171, 10.1016/S0022-3956(00)00016-9 · DOI · Paper page
- Zunszain, 2013, Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties, Mol. Psychiatry, 18, 1236, 10.1038/mp.2013.87 · DOI
Cited by
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Aleksandrova, L. R., Phillips, A. G., & Wang, Y. T. (2017) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.160175 · Cited by 228
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.010 · Cited by 219
Tabuteau, H., Jones, A., Anderson, A., Jacobson, M., & Iosifescu, D. V. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.21080800 · Cited by 140
Ma, W., Song, J., Wang, H., Shi, F., Zhou, N., Jiang, J., Xu, Y., Zhang, L., Yang, L., & Zhou, M. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.04.006 · Cited by 134
Metadata
- Authors
- Machado-Vieira, R., Henter, I. D., & Zarate Jr., C. A.
- Venue
- Progress in Neurobiology
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 152
- Pages
- 21-37
- ISSN
- 0301-0082 (ISSN-L)
- OpenAlex
- W2208668986
- Cited by
- 154
- References
- 79
- FWCI
- 10.36
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- National Institute of Mental Health
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New targets for rapid antidepressant action. https://app.cochat.ai/papers/10.1016/j.pneurobio.2015.12.001
- The paper
- Machado-Vieira, R., Henter, I. D., & Zarate Jr., C. A. (2017). New targets for rapid antidepressant action. Progress in Neurobiology. https://doi.org/10.1016/j.pneurobio.2015.12.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.